JP2009545601A5 - - Google Patents

Download PDF

Info

Publication number
JP2009545601A5
JP2009545601A5 JP2009522883A JP2009522883A JP2009545601A5 JP 2009545601 A5 JP2009545601 A5 JP 2009545601A5 JP 2009522883 A JP2009522883 A JP 2009522883A JP 2009522883 A JP2009522883 A JP 2009522883A JP 2009545601 A5 JP2009545601 A5 JP 2009545601A5
Authority
JP
Japan
Prior art keywords
composition
administered
naphthyridine
pyrrolidinyl
methylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009522883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009545601A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/017344 external-priority patent/WO2008016702A2/en
Publication of JP2009545601A publication Critical patent/JP2009545601A/ja
Publication of JP2009545601A5 publication Critical patent/JP2009545601A5/ja
Pending legal-status Critical Current

Links

JP2009522883A 2006-08-02 2007-08-02 (+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の組合せ使用 Pending JP2009545601A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83523906P 2006-08-02 2006-08-02
US87376006P 2006-12-08 2006-12-08
PCT/US2007/017344 WO2008016702A2 (en) 2006-08-02 2007-08-02 Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013198807A Division JP2014040437A (ja) 2006-08-02 2013-09-25 (+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の組合せ使用

Publications (2)

Publication Number Publication Date
JP2009545601A JP2009545601A (ja) 2009-12-24
JP2009545601A5 true JP2009545601A5 (US20070167479A1-20070719-C00034.png) 2011-10-06

Family

ID=38859094

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009522883A Pending JP2009545601A (ja) 2006-08-02 2007-08-02 (+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の組合せ使用
JP2013198807A Pending JP2014040437A (ja) 2006-08-02 2013-09-25 (+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の組合せ使用
JP2015219880A Expired - Fee Related JP6189911B2 (ja) 2006-08-02 2015-11-09 (+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の組合せ使用
JP2017150849A Ceased JP2017226683A (ja) 2006-08-02 2017-08-03 (+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の組合せ使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013198807A Pending JP2014040437A (ja) 2006-08-02 2013-09-25 (+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の組合せ使用
JP2015219880A Expired - Fee Related JP6189911B2 (ja) 2006-08-02 2015-11-09 (+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の組合せ使用
JP2017150849A Ceased JP2017226683A (ja) 2006-08-02 2017-08-03 (+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の組合せ使用

Country Status (12)

Country Link
US (3) US20080063642A1 (US20070167479A1-20070719-C00034.png)
EP (2) EP2049109B1 (US20070167479A1-20070719-C00034.png)
JP (4) JP2009545601A (US20070167479A1-20070719-C00034.png)
CA (1) CA2659861A1 (US20070167479A1-20070719-C00034.png)
CY (1) CY1119309T1 (US20070167479A1-20070719-C00034.png)
DK (1) DK2049109T3 (US20070167479A1-20070719-C00034.png)
ES (1) ES2556677T3 (US20070167479A1-20070719-C00034.png)
HU (1) HUE026693T2 (US20070167479A1-20070719-C00034.png)
MX (1) MX344865B (US20070167479A1-20070719-C00034.png)
PL (1) PL2049109T3 (US20070167479A1-20070719-C00034.png)
SI (1) SI2049109T1 (US20070167479A1-20070719-C00034.png)
WO (1) WO2008016702A2 (US20070167479A1-20070719-C00034.png)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3053579A1 (en) * 2004-03-15 2016-08-10 Sunesis Pharmaceuticals, Inc. Use of sns-595 for treating ovarian cancer
US8580814B2 (en) 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
WO2007146335A2 (en) 2006-06-12 2007-12-21 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
WO2009054935A1 (en) 2007-10-22 2009-04-30 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
US20110008371A1 (en) * 2007-12-10 2011-01-13 Sunesis Pharmaceuticals, Inc Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
SG10201504789RA (en) 2008-12-31 2015-07-30 Sunesis Pharmaceuticals Inc Method Of Preparing (+)-1,4-Dihydro-7-[(3s,4s)-3methoxy-4-(Methylamino)-1-Pyrrolidinyl]-4-Oxo-1-(2-Thiazolyl)-1,8-Naphthyridine-3-Carboxylic Acid
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
WO2011056566A2 (en) * 2009-10-26 2011-05-12 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
PT2506840T (pt) * 2009-12-04 2021-04-27 Oncoc4 Inc Utilizações de inibidores de fatores induzíveis de hipoxia
RU2550663C2 (ru) * 2013-02-13 2015-05-10 Владимир Владимирович Савостьянов Способ гормонально-лучевой подготовки больных хроническим лимфолейкозом к последующей химиотерапии
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
EP3191187B1 (en) 2014-09-09 2021-07-28 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
KR102597989B1 (ko) * 2014-12-04 2023-11-02 얀센 바이오테크 인코포레이티드 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체
EP3297624B1 (en) 2015-05-18 2021-03-03 Syn-Nat Products Enterprise LLC A pharmaceutical co-crystal and use thereof
MX2017014810A (es) 2015-05-20 2018-05-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
AU2016279096B2 (en) * 2015-06-19 2021-01-07 Syn-Nat Products Enterprise LLC Composition containing carboplatin and use
EP3297636B1 (en) 2015-06-19 2021-02-17 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
IL256242B1 (en) 2015-06-22 2024-05-01 Janssen Biotech Inc Combination therapies for HEME malignancies with anti-CD38 antibodies and sorbibin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CN116854745A (zh) 2015-06-25 2023-10-10 新纳特产品公司 药物共晶组合物及其用途
ES2912729T3 (es) 2015-11-03 2022-05-27 Janssen Biotech Inc Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
AU2018359527A1 (en) 2017-10-31 2020-05-07 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5382525A (en) * 1992-11-27 1995-01-17 American Air Liquide Method of effecting increased performance of diagnostic enzyme reaction systems using noble gases
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
RO117793B1 (ro) 1994-06-14 2002-07-30 Dainippon Pharmaceutical Co Derivati de acid piridoncarboxilic si compozitie farmaceutica care ii contine
JPH10173986A (ja) 1996-12-16 1998-06-26 Sony Corp 移動体撮影装置
US6291643B1 (en) * 1997-06-05 2001-09-18 Board Of Reports, The University Of Texas System Apaf-1 an activator of caspase-3
US6171857B1 (en) * 1997-10-17 2001-01-09 Brown University Research Foundatiion Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
US6670144B1 (en) * 1999-02-26 2003-12-30 Cyclacel, Ltd. Compositions and methods for monitoring the phosphorylation of natural binding partners
WO2000050453A1 (en) * 1999-02-26 2000-08-31 The Johns Hopkins University A novel inhibitor of programmed cell death
US7163801B2 (en) * 1999-09-01 2007-01-16 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
AU2001296558A1 (en) * 2000-10-03 2002-04-15 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
EP3053579A1 (en) 2004-03-15 2016-08-10 Sunesis Pharmaceuticals, Inc. Use of sns-595 for treating ovarian cancer
US20050222267A1 (en) * 2004-04-01 2005-10-06 Truong Van H Solution based methacholine formulations
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
WO2007028171A1 (en) * 2005-09-02 2007-03-08 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer

Similar Documents

Publication Publication Date Title
JP2009545601A5 (US20070167479A1-20070719-C00034.png)
JP2014040437A5 (US20070167479A1-20070719-C00034.png)
ES2964764T3 (es) Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino
JP2009515901A5 (US20070167479A1-20070719-C00034.png)
JP2012521435A5 (US20070167479A1-20070719-C00034.png)
ES2384789T3 (es) Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas
JP2009539769A5 (US20070167479A1-20070719-C00034.png)
JP2015227351A5 (US20070167479A1-20070719-C00034.png)
US20120157472A1 (en) Method for treating colorectal cancer
JP2014148535A5 (US20070167479A1-20070719-C00034.png)
JP2006523216A5 (US20070167479A1-20070719-C00034.png)
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2008530248A5 (US20070167479A1-20070719-C00034.png)
JP2009510171A5 (US20070167479A1-20070719-C00034.png)
JP2009545600A5 (US20070167479A1-20070719-C00034.png)
JP2019511526A5 (US20070167479A1-20070719-C00034.png)
JP2011500805A5 (US20070167479A1-20070719-C00034.png)
JP2011515481A5 (US20070167479A1-20070719-C00034.png)
US20140093585A1 (en) Parp inhibitors for the treatment of cipn
JP2020523356A5 (US20070167479A1-20070719-C00034.png)
JP2014533277A5 (US20070167479A1-20070719-C00034.png)
JP2019511529A5 (US20070167479A1-20070719-C00034.png)
JP2015057397A (ja) 併用療法における(+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の使用方法
Bertolini et al. Acute cardiotoxicity during capecitabine treatment: a case report
JP2006514681A5 (US20070167479A1-20070719-C00034.png)